Evidence map›Paper›PMID 34450049›Full record

ArticleCancer cell2021

ILC3 plasticity in microbiome-mediated tumor progression and immunotherapy.

Lei Shen, Youqiong Ye, Hongxiang Sun, Bing Su

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Microbiome Modulation withJournal of microbiology and biotechnology · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Lei ShenShanghai Institute of Immunology, Department of Immunology and Microbiology, and The State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Youqiong YeShanghai Institute of Immunology, Department of Immunology and Microbiology, and The State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Shanghai Jiao Tong University School of Medicine-Yale Institute for Immune Metabolism (SYIIM), Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Hongxiang SunShanghai Institute of Immunology, Department of Immunology and Microbiology, and The State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Shanghai Jiao Tong University School of Medicine-Yale Institute for Immune Metabolism (SYIIM), Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Translational Medicine Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Bing SuShanghai Institute of Immunology, Department of Immunology and Microbiology, and The State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Shanghai Jiao Tong University School of Medicine-Yale Institute for Immune Metabolism (SYIIM), Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Translational Medicine Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Electronic address: bingsu@sjtu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The precise role of intestinal ILC3s in cancer remains largely unknown. Published in Cell, Goc et al. describe ILC3 function and plasticity in tumors. ILC3s may lose their identity and thus become either ILC1s or exhausting-ILC3s, which could in turn reshape the gut microbiome for colorectal cancer progression and immunotherapy resistance.

Indexed as

Gastrointestinal MicrobiomeLymphocytesImmunity, InnateImmunotherapy

Identifiers

PMID34450049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.